CRDF
Cardiff Oncology·NASDAQ
--
--(--)
--
--(--)
6.67 / 10
Netural
Capital flow assessment yields 7.78/10, denoting robust fund flow characteristics. Strengths in overall, block, Small, and Extra-large trends confront pressures from Medium and Large patterns, resulting in positive liquidity outlook. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Buy(100.0%) across 1 coverage providers, supported by 5.55 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-25
InstitutionPiper Sandler
Times predicted1
Historical Win Rate100.0%
What is the market sentiment for CRDF?
- CRDF holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.67/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
